Nothing Special   »   [go: up one dir, main page]

MX2021002264A - Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt. - Google Patents

Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.

Info

Publication number
MX2021002264A
MX2021002264A MX2021002264A MX2021002264A MX2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A
Authority
MX
Mexico
Prior art keywords
methyl
ylethynyl
pyridazin
imidazo
trifluoromethyl
Prior art date
Application number
MX2021002264A
Other languages
Spanish (es)
Inventor
Christopher K Murray
Leonard W Rozamus
John J Chaber
Pradeep Sharma
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021002264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2021002264A publication Critical patent/MX2021002264A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methy lpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyljbenzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methyl piperazi n-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein. The instant application is directed to novel crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl}phenyl}benzamide and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyi-N-{4-[(4-methy lpiperazin-1 -yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, compositions comprising such crystalline forms, and to methods of their preparation and use.
MX2021002264A 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt. MX2021002264A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US201361788208P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2021002264A true MX2021002264A (en) 2021-05-27

Family

ID=50929140

Family Applications (10)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (en) 2012-12-12 2013-12-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002259A MX2021002259A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002255A MX2021002255A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002253A MX2021002253A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002264A MX2021002264A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002254A MX2021002254A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002261A MX2021002261A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002257A MX2021002257A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002258A MX2021002258A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002256A MX2021002256A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.

Family Applications Before (4)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (en) 2012-12-12 2013-12-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002259A MX2021002259A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002255A MX2021002255A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002253A MX2021002253A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2021002254A MX2021002254A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002261A MX2021002261A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002257A MX2021002257A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002258A MX2021002258A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
MX2021002256A MX2021002256A (en) 2012-12-12 2015-06-12 Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.

Country Status (9)

Country Link
US (9) US9493470B2 (en)
JP (4) JP6447508B2 (en)
CN (2) CN105188701A (en)
CA (3) CA3167093A1 (en)
CL (1) CL2015001643A1 (en)
HK (1) HK1218878A1 (en)
MX (10) MX359147B (en)
NZ (1) NZ709648A (en)
WO (2) WO2014093583A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634923C (en) 2005-12-23 2015-05-05 Ariad Pharmaceuticals, Inc. Acetylenic bicyclic heteroaryl compounds useful as kinase inhibitors
TWI568722B (en) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 Triazolone compounds as mpges-1 inhibitors
CA3167093A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2014286047B2 (en) 2013-07-04 2018-02-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496995A (en) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 Method for preparing 3-ethynylimidazo[1,2-b]pyridazine
AU2017376629B2 (en) * 2016-12-15 2021-11-25 Ariad Pharmaceuticals, Inc. Benzimidazole compounds as c-Kit inhibitors
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
WO2018232501A1 (en) * 2017-06-20 2018-12-27 Apotex Inc. Crystalline forms of ponatinib hydrochloride
IL277718B1 (en) * 2018-04-02 2024-10-01 Stealth Biotherapeutics Corp Crystalline dipeptides useful in the synthesis of elamipretide
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
CR20210287A (en) 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (en) * 2019-12-13 2020-12-01 山东铂源药业有限公司 Synthetic method of ponatinib intermediate 3-ethynylimidazo [1,2-b ] pyridazine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
CN1177840C (en) 1999-11-08 2004-12-01 先灵公司 Process for preparing N-(4-hydroxy-phenyl)-N'-(4'-aminophenyl)-piperrazine
HN2001000008A (en) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
DE10021246A1 (en) 2000-04-25 2001-10-31 Schering Ag New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
TW200418466A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2004292773A1 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
NZ546782A (en) 2003-12-05 2010-04-30 Biovitrum Ab Improved synthesis of 2-substituted adenosines such as spongosine
ATE402705T1 (en) 2003-12-24 2008-08-15 Astrazeneca Ab PYRIMIDINES WITH TIE2 (TEK) ACTIVITY
ES2317079T3 (en) 2003-12-24 2009-04-16 Astrazeneca Ab PYRIMIDINS WITH ACTIVITY TIE2 (TEK).
WO2005097773A1 (en) 2004-04-07 2005-10-20 Applied Research Systems Ars Holding N.V. 1,1’-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP2008534565A (en) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Aminopyrimidine derivatives having Tie2 inhibitory activity
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
CA2618513A1 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
CA2634923C (en) * 2005-12-23 2015-05-05 Ariad Pharmaceuticals, Inc. Acetylenic bicyclic heteroaryl compounds useful as kinase inhibitors
SI1973545T1 (en) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
EA200870514A1 (en) 2006-05-08 2009-04-28 Ариад Фармасьютикалз, Инк. ACETYLENE HETEROARRYL COMPOUNDS
ES2555515T3 (en) 2006-05-08 2016-01-04 Ariad Pharmaceuticals, Inc. Monocyclic heteroaryl compounds
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20100273772A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20120316137A1 (en) * 2009-10-30 2012-12-13 Ariad Pharmaceuticals, Inc. Methods and Compositions for Treating Cancer
KR20140022062A (en) 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 Methods and compositions for treat1ng parkinson's disease
AU2012240026A1 (en) * 2011-04-07 2013-09-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
WO2013162727A1 (en) 2012-04-25 2013-10-31 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
CA3167093A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
US11192897B2 (en) 2021-12-07
US20210277012A1 (en) 2021-09-09
US11279705B2 (en) 2022-03-22
JP7042175B2 (en) 2022-03-25
CA3167093A1 (en) 2014-06-12
MX2021002255A (en) 2021-05-27
WO2014093579A3 (en) 2014-07-10
US20170190707A1 (en) 2017-07-06
JP2023179498A (en) 2023-12-19
JP7352841B2 (en) 2023-09-29
MX2021002257A (en) 2021-05-27
WO2014093583A2 (en) 2014-06-19
US20210340149A1 (en) 2021-11-04
CA2815506A1 (en) 2014-06-12
US20240083902A1 (en) 2024-03-14
CL2015001643A1 (en) 2015-10-02
US20210277011A1 (en) 2021-09-09
MX2021002256A (en) 2021-05-27
US10125136B2 (en) 2018-11-13
CN115043843A (en) 2022-09-13
CA2815506C (en) 2018-12-11
JP2022037122A (en) 2022-03-08
MX359147B (en) 2018-09-17
US9493470B2 (en) 2016-11-15
US20150315194A1 (en) 2015-11-05
JP2016503010A (en) 2016-02-01
US20210024527A1 (en) 2021-01-28
NZ709648A (en) 2020-05-29
CA3022250A1 (en) 2014-06-12
HK1218878A1 (en) 2017-03-17
MX2015007578A (en) 2016-03-21
US11192896B2 (en) 2021-12-07
MX2021002253A (en) 2021-05-27
CN105188701A (en) 2015-12-23
JP2018168191A (en) 2018-11-01
WO2014093579A2 (en) 2014-06-19
JP6447508B2 (en) 2019-01-09
US10662197B2 (en) 2020-05-26
MX2021002254A (en) 2021-05-27
WO2014093583A3 (en) 2014-08-07
MX2021002259A (en) 2021-05-27
MX2021002261A (en) 2021-05-27
US20210277010A1 (en) 2021-09-09
US20190169196A1 (en) 2019-06-06
MX2021002258A (en) 2021-05-27
US11384086B2 (en) 2022-07-12
US11192895B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
MX2021002258A (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
PH12015502792A1 (en) Crystalline bromodomain inhibitors
EA201691242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
IL232462A (en) 2-(1,2,3-triazol-2-yl) benzamide and 3-(1,2,3-triazol-2-yl) picolinamide derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
HK1214822A1 (en) Novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient 3-(4-())-4-
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MX2018006903A (en) Pharmaceutical composition comprising a potent inhibitor of urat1.
IN2014DN09347A (en)
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
PH12017501832A1 (en) Stabilized pharmaceutical composition
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
MX2014002141A (en) N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides.
IN2013CH01248A (en)
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids